We are live on ! Find out more
PSTV

Plus Therapeutics
PSTV

Delisted

PSTV was delisted on the 31st of July, 2026.

Back to rankings

6 hedge funds and large institutions have $4.51M invested in Plus Therapeutics in 2017 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 0 reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more funds holding

Funds holding: 4 → 6 (+2)

0% more ownership

Funds ownership: 0% → 0% (+0%)

0% less capital invested

Capital invested by funds: $4.51M → $4.51M (-$6.07K)

Holders
6
Holders Change
+2
Holders Change %
+50%
% of All Funds
0.15%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
3
Reduced
–
Closed
–
Calls
$28K
Puts
–
Net Calls
+$28K
Net Calls Change
+$38K

Top Buyers

Rank Fund Capital Flow
1
PCM
Perkins Capital Management
Minnesota
+$606K
2
SM
Sabby Management
Florida
+$404K
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$202K
4
Renaissance Technologies
Renaissance Technologies
New York
+$202K
5
Vanguard Group
Vanguard Group
Pennsylvania
+$202K

Top Sellers

Rank Fund Capital Flow
1
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$74K
2
VKH
Virtu KCG Holdings
New York
-$73K
3
Citadel Advisors
Citadel Advisors
Florida
-$25K
Name Holding Trade Value Shares
Change 		Change in
Stake
SM
1
Sabby Management
Florida
$1.79M +$404K +2 +29%
PCM
2
Perkins Capital Management
Minnesota
$962K +$606K +3 +150%
Vanguard Group
3
Vanguard Group
Pennsylvania
$674K +$202K +1 +50%
BlackRock
4
BlackRock
New York
$353K – – –
Geode Capital Management
5
Geode Capital Management
Massachusetts
$188K +$202K +1 New
Renaissance Technologies
6
Renaissance Technologies
New York
$165K +$202K +1 New
Creative Planning
7
Creative Planning
Kansas
$86K – – –
Northern Trust
8
Northern Trust
Illinois
$61K – – –
TSS
9
Two Sigma Securities
New York
$59K – – –
FPF
10
FNY Partners Fund
New York
$52K – – –
Royal Bank of Canada
11
Royal Bank of Canada
Ontario, Canada
$28K – – –
HighTower Advisors
12
HighTower Advisors
Illinois
$17K – – –
California Public Employees Retirement System
13
California Public Employees Retirement System
California
$15K – – –
UB
14
UMB Bank
Missouri
$14K – – –
MCM
15
Marathon Capital Management
Maryland
$12K – – –
IP
16
Intellectus Partners
California
$11K – – –
Simplex Trading
17
Simplex Trading
Illinois
$9K – – –
PMFA
18
Plante Moran Financial Advisors
Michigan
$4K – – –
Barclays
19
Barclays
United Kingdom
$2K – – –
Morgan Stanley
20
Morgan Stanley
New York
$2K – – –
Bank of America
21
Bank of America
North Carolina
$1K – – –
New York State Common Retirement Fund
22
New York State Common Retirement Fund
New York
$1K – – –
TDC
23
Thompson Davis & Co
Virginia
$1K – – –
UBS Group
24
UBS Group
Switzerland
$1K – – –
Wells Fargo
25
Wells Fargo
California
$1K – – –
1
2

PSTV Hedge Fund Activity: Q2 2017 in Review

6 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Plus Therapeutics (PSTV) for Q2 2017, worth a combined $4.51M — down 0.13% from $4.51M a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new PSTV positions and 0 closed out — a net gain of 2 holders — while 3 added to existing stakes and 0 trimmed.

The largest buyer was Perkins Capital Management, adding an estimated $606K. The largest seller was Jacobs Levy Equity Management, cutting an estimated $74K.

  • 6 institutional investors held Plus Therapeutics (PSTV) as of Q2 2017, up from 4 in Q1 2017.
  • Funds reported $4.51M of Plus Therapeutics stock for Q2 2017, down 0.13% quarter-over-quarter.
  • 2 funds opened new Plus Therapeutics positions in Q2 2017 and 0 closed out, a net change of +2 holders.
  • The largest Plus Therapeutics buyer in Q2 2017 was Perkins Capital Management, an estimated $606K added.
  • The largest Plus Therapeutics seller in Q2 2017 was Jacobs Levy Equity Management, an estimated $74K sold.

Based on aggregated 13F filings for Q2 2017.